在心力衰竭和植入式心脏转换器-除器患者的Vericiguat
Carlos Escobar1, Jesús Saldaña1, José Luis Merino1
1Cardiology Department, Arrhythmia Unit, University Hospital La Paz, Madrid, Spain.
Drugs in context
|March 13, 2025
概括
韦里西瓜特在心力衰竭患者中表现出良好的安全概况,其中包括减少喷射率 (HFrEF) 和 implantable cardioverter-defibrillators. 分析表明,对于这些患者来说,心室心律失常的潜在减少.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 医疗器械 医疗器械
背景情况:
- 减少喷射分数 (HFrEF) 的心力衰竭带来重大风险,包括心室心律不整.
- 植入式心脏转换器-除器 (ICD) 对于管理HFrEF患者心律失常风险至关重要.
- 韦里西瓜特是HFrEF的新疗法,但其对ICD患者心律不整的具体影响需要研究.
研究的目的:
- 评估HFrEF和ICD患者中 vericiguat的有效性和耐受性.
- 评估 vericiguat对本患者队列中心室失常症的发生和负担的影响.
- 在患有ICD的患者中,分析添加到标准HFrEF疗法时的 vericiguat的安全性.
主要方法:
- 在西班牙一所高等大学医院,对14名HFrEF和ICD患者进行了回顾性分析,这些患者接受了 vericiguat治疗.
- 收集了关于患者人口统计,基线特征,同时治疗心力衰竭和不良事件的数据.
- 在接受治疗前和治疗期间评估心室心律不整以及相关的临床结果.
主要成果:
- 维里西瓜特一般耐受良好,副作用率较低,例如低血压和功能受损.
- 观察到心室心律不整的发病率有所降低,两名患者的发病率有所减少.
- 七名患者成功达到每日10毫克的目标剂量,表明良好的坚持和耐受性.
结论:
- 在与标准心力衰竭治疗一起使用时,Vericiguat在患有HFrEF和ICD的患者中表现出良好的安全性.
- 在这种高风险人群中,Vericiguat可能在降低心室心律失常的风险和负担方面提供潜在的益处.
- 需要进一步的前性研究来证实这些发现,并阐明观察到的抗失常效应背后的机制.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
481
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
481
01:22Heart Failure Drugs: β-Blockers
300
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
300
01:22Heart Failure Drugs: Diuretics
313
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
313
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
356
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
356
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
695
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
695
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.0K